- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01179984
Bard® LifeStent® Vascular Stent Delivery System Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Single-arm, non-randomized, prospective, multi-center study using the Bard® LifeStent® Vascular Stent Delivery System in subjects with lifestyle-limiting claudication or ischemic rest pain that are candidates for percutaneous transluminal angioplasty (PTA) and stenting with lesion(s) in the infra-inguinal segment (superficial femoral artery (SFA) and/or proximal popliteal artery). Subjects will be treated with PTA followed by implantation of the Bard® LifeStent® Vascular Stent.
Clinical follow-up for all subjects will be performed prior to hospital discharge, 30-days, and 12-, 24-, and 36-months post-index procedure.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Univ. Prof. Dr. Johannes Lammer
-
-
-
-
-
Berlin, Germany, 13347
- Dr. Henrik Schroeder
-
Hamburg, Germany, 22527
- Dr. Hans Krankenberg
-
Kaiserslautern, Germany, 67657
- Dr. Rainer Schmiedel
-
Leipzig, Germany, 04103
- Prof. Dr. med. Dietrich Pfeiffer
-
Münster, Germany, 48149
- Prof. Dr. Holger Reinecke
-
Rosenheim, Germany, 83022
- Prof. Dr. Gunnar Tepe
-
-
Baden Württemberg
-
Bad Krozingen, Baden Württemberg, Germany, 79189
- Herzzentrum Bad Krozingen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject or legal representative has been informed of the nature of the evaluation, agrees to its provisions, and has signed the informed consent form (ICF).
- Subject agrees to comply with the protocol-mandated follow-up procedures and visits.
- The subject is ≥ 21 years old.
- Female subjects of childbearing potential must have a negative urine or serum pregnancy test within seven days prior to index procedure. Female subjects who are surgically sterile or post-menopausal are exempt from having a pregnancy test.
- The subject has lifestyle-limiting claudication or ischemic rest pain defined as: Rutherford Category1 2-4 (moderate claudication to ischemic rest pain).
- The target lesion(s) has angiographic evidence of stenosis or restenosis ≥50% or occlusion (by visual estimate) and is amenable to PTA and stenting.
- The total treated segment(s) must be ≤ 240 mm.
- The target vessel reference diameter is ≥4.0 mm and ≤6.5 mm (by visual estimate) and therefore appropriate for treatment with available stent diameters of 6.0 mm and 7.0 mm.
- There is angiographic evidence of at least one vessel runoff to the foot (at the level of the malleolus).
Exclusion Criteria:
- The subject is unable or unwilling to provide informed consent or is unable or unwilling to comply with the study follow-up procedure and visits.
- The subject has claudication or critical limb ischemia described as Rutherford Category1 1 (mild claudication), 5 (minor tissue loss) or 6 (major tissue loss).
- The subject has a known contraindication (including allergic reaction) or sensitivity to antiplatelet/anticoagulant medications, nickel, titanium or tantalum.
- The subject has a known sensitivity to contrast media that is not amenable to pretreatment with steroids or/and antihistamines.
- The subject has a history of bleeding diatheses or coagulopathy.
- The subject has concomitant renal failure with a creatinine of >2.5 mg/dL.
- The subject has concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus (SLE), or deep vein thrombosis (DVT) at the time of the study procedure.
- The subject is receiving dialysis or immunosuppressive therapy.
- The subject is participating in an investigational drug or another investigational device study.
- The subject has another medical condition, which, in the opinion of the investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with limited life expectancy of less than two years.
- The subject has extensive peripheral vascular disease, which, in the opinion of the investigator, precludes safe insertion of an introducer sheath.
- The target lesion(s) is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion(s).
- The subject has angiographic evidence of poor inflow, which would be deemed inadequate to support a vascular bypass graft.
- The subject is diagnosed with septicemia at the time of the study procedure.
- Patients with a stent previously implanted into the target vessel.
- Bilateral disease in the native SFA and/or proximal popliteal artery where both limbs meet the inclusion/exclusion criteria and it is planned to treat both limbs within 30 days. Note: One limb may be enrolled in the study, but only if the second limb is planned to be treated after the 30-day follow-up visit has taken place. The limb that may be enrolled has to be the limb with the more severe lesion and the reasons for treating this specific limb will need to be stated in the CRF.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PTA and study stent
Bard® LifeStent® Vascular Stent System
|
Stent Implantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute Effectiveness: Percentage of Stents With Successful Delivery
Time Frame: At implantation (Day 0)
|
Effectiveness: Acute effectiveness defined as the successful delivery of the stent with the post-deployment stent length being within 10% of the pre-deployment length. |
At implantation (Day 0)
|
(Safety) Freedom From Occurrence of Death, Amputation and TVR/TLR at 30-days Post-index Procedure.
Time Frame: 30 day follow-up
|
Safety: Freedom from occurrence of death, amputation and TVR/TLR at 30-days post-index procedure. |
30 day follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Target Lesion Patency
Time Frame: 12 months post-index procedure
|
Percentage of participants with Primary Target Lesion Patency (TLP) at 12 months post-index procedure
|
12 months post-index procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas Zeller, MD, Herzzentrum Bad Krozingen, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BPV-09-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Vascular Disease
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
SensomeRecruitingPeripheral Vascular DiseaseBelgium
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States
-
Biotronik AGBiotronik, Inc.UnknownPeripheral Vascular Disease | Peripheral Artery DiseaseGermany, Belgium, Austria, Switzerland
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
University of MichiganTerminatedPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
Clinical Trials on Bard® LifeStent® Vascular Stent System
-
C. R. BardCompletedPeripheral Arterial Disease | Intermittent ClaudicationGermany
-
C. R. BardCompletedPeripheral Artery DiseaseGermany
-
C. R. BardTerminatedSuperficial Femoral Artery StenosisUnited States
-
C. R. BardMedicon, Inc.Completed
-
W.L.Gore & AssociatesCompleted
-
Medical University of ViennaUnknownStent Restenosis | Intimal HyperplasiaAustria
-
Cook Group IncorporatedCompleted
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States
-
Abbott Medical DevicesBaim Institute for Clinical ResearchWithdrawnWith de Novo or Restenotic Lesions in the Common and/or External Iliac Arteries
-
C. R. BardCompletedPeripheral Artery DiseaseGermany